- Home
- ACLX
ACLX
Arcellx Inc.
as 05-20-2024 4:00pm EST
$.
+$.
+.%
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 2.9B | IPO Year: | 2022 |
| Target Price: | $77.27 | AVG Volume (30 days): | 471.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 13 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $30.74 - $75.10 | Next Earning Date: | 05-09-2024 |
| Revenue: | $131,663,000 | Revenue Growth: | 635.05% |
| Revenue Growth (this year): | -1.52% | Revenue Growth (next year): | 15.39% |
Share on Social Networks:
Stock Insider Trading Activity of Arcellx Inc. (ACLX)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $53.55 | 100 | $5,355.00 | 8,938 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $52.63 | 500 | $26,314.00 | 9,038 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $51.48 | 10,481 | $539,541.97 | 9,538 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | May 1 '24 | Sell | $50.99 | 7,087 | $361,345.58 | 20,019 | SEC Form 4 |
| Ware Olivia C | ACLX | Director | Apr 16 '24 | Sell | $56.03 | 2,612 | $146,352.97 | 0 | SEC Form 4 |
| Ware Olivia C | ACLX | Director | Apr 16 '24 | Sell | $55.36 | 6,790 | $375,906.62 | 2,612 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Apr 1 '24 | Sell | $68.42 | 2,711 | $185,476.05 | 69,253 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Apr 1 '24 | Sell | $67.58 | 5,456 | $368,731.21 | 71,964 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Apr 1 '24 | Sell | $66.67 | 14,919 | $994,679.57 | 77,420 | SEC Form 4 |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Mar 18 '24 | Sell | $69.03 | 3,782 | $261,063.14 | 12,528 | SEC Form 4 |
| Gilson Michelle | ACLX | CHIEF FINANCIAL OFFICER | Mar 18 '24 | Sell | $69.73 | 3,043 | $212,192.35 | 9,485 | SEC Form 4 |
| Ware Olivia C | ACLX | Director | Mar 15 '24 | Sell | $69.44 | 1,900 | $131,932.20 | 7,100 | SEC Form 4 |
| Ware Olivia C | ACLX | Director | Mar 15 '24 | Sell | $70.36 | 3,763 | $264,768.44 | 3,337 | SEC Form 4 |
| Ware Olivia C | ACLX | Director | Mar 15 '24 | Sell | $70.99 | 3,337 | $236,881.28 | 0 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Feb 8 '24 | Sell | $64.46 | 2,967 | $191,251.34 | 30,303 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Feb 8 '24 | Sell | $63.40 | 3,688 | $233,810.72 | 33,270 | SEC Form 4 |
| Heery Christopher | ACLX | CHIEF MEDICAL OFFICER | Feb 8 '24 | Sell | $62.29 | 3,456 | $215,289.79 | 36,958 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Feb 8 '24 | Sell | $62.29 | 13,010 | $810,451.45 | 117,394 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Feb 8 '24 | Sell | $63.40 | 13,886 | $880,340.46 | 103,508 | SEC Form 4 |
| Elghandour Rami | ACLX | SEE REMARKS | Feb 8 '24 | Sell | $64.46 | 11,169 | $719,948.16 | 92,339 | SEC Form 4 |
| Elghandour Rami | ACLX | See Remarks | Jan 4 '24 | Sell | $55.27 | 29,073 | $1,606,803.66 | 60,193 | SEC Form 4 |
| Heery Christopher | ACLX | Chief Medical Officer | Jan 4 '24 | Sell | $55.27 | 7,598 | $419,925.50 | 17,859 | SEC Form 4 |
| Gilson Michelle | ACLX | Chief Financial Officer | Jan 4 '24 | Sell | $55.27 | 8,514 | $470,550.90 | 16,310 | SEC Form 4 |
| Carroll Jill | ACLX | Director | Dec 14 '23 | Sell | $49.13 | 504,263 | $24,774,441.19 | 1,983,411 | SEC Form 4 |
Latest Arcellx Inc. News
ACLX Breaking Stock News: Dive into ACLX Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Stifel Adjusts Price Target on Arcellx to $83 From $82, Maintains Buy Rating
MT Newswires
6 days ago
Evercore ISI Starts Arcellx With Outperform Rating
Simply Wall St.
8 days ago
Arcellx First Quarter 2024 Earnings: Beats Expectations
GuruFocus.com
10 days ago
Arcellx Inc (ACLX) Q1 2024 Earnings: Narrower Losses and Revenue Surge
Clinical Trials Arena
11 days ago
Kite and Arcellx prepare to launch Phase III multiple myeloma trial
Zacks
11 days ago
Arcellx, Inc. (ACLX) Reports Q1 Loss, Tops Revenue Estimates
Business Wire
11 days ago
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
Business Wire
11 days ago